Heterogeneous Nuclear Ribonucleoprotein K Is Involved in the Estrogen-Signaling Pathway in Breast Cancer
Open Access
- 4 March 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5), 2581
- https://doi.org/10.3390/ijms22052581
Abstract
Heterogeneous nuclear ribonucleoprotein K (hnRNPK) transcripts are abundant in estrogen receptor (ER)- or progesterone receptor (PR)-positive breast cancer. However, the biological functions of hnRNPK in the ER-mediated signaling pathway have remained largely unknown. Therefore, this study analyzes the functions of hnRNPK expression in the ER-mediated signaling pathway in breast cancer. We initially evaluated hnRNPK expression upon treatment with estradiol (E2) and ICI 182,780 in the ERα-positive breast carcinoma cell line MCF-7. The results revealed that E2 increased hnRNPK; however, hnRNPK expression was decreased with ICI 182,780 treatment, indicating estrogen dependency. We further evaluated the effects of hnRNPK knockdown in the ER-mediated signaling pathway in MCF-7 cells using small interfering RNAs. The results revealed that hnRNPK knockdown decreased ERα expression and ERα target gene pS2 by E2 treatment. As hnRNPK interacts with several other proteins, we explored the interaction between hnRNPK and ERα, which was demonstrated using immunoprecipitation and proximity ligation assay. Subsequently, we immunolocalized hnRNPK in patients with breast cancer, which revealed that hnRNPK immunoreactivity was significantly higher in ERα-positive carcinoma cells and significantly lower in Ki67-positive or proliferative carcinoma cells. These results indicated that hnRNPK directly interacted with ERα and was involved in the ER-mediated signaling pathway in breast carcinoma. Furthermore, hnRNPK expression could be an additional target of endocrine therapy in patients with ERα-positive breast cancer.Funding Information
- Japan Society for the Promotion of Science (JSPS) Kakenhi (19K16548)
This publication has 24 references indexed in Scilit:
- HNRNPK inhibits gastric cancer cell proliferation through p53/p21/CCND1 pathwayOncotarget, 2017
- Heterogeneous nuclear ribonucleoprotein K is associated with poor prognosis and regulates proliferation and apoptosis in bladder cancerJournal of Cellular and Molecular Medicine, 2016
- Tamoxifen Resistance: Emerging Molecular TargetsInternational Journal of Molecular Sciences, 2016
- Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progressionCancer Letters, 2014
- Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulatorsMolecular Systems Biology, 2013
- Personalized Medicine: The Road AheadClinical Breast Cancer, 2011
- Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinomaInternational Journal of Cancer, 2009
- Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancerBritish Journal of Cancer, 2006
- hnRNP K: One protein multiple processesBioEssays, 2004
- Growth Factors Regulate Heterogeneous Nuclear Ribonucleoprotein K Expression and FunctionOnline Journal of Public Health Informatics, 2001